2010/06/03 by Alison Oliveto, W. Brooks Gentry, Rhonda Pruzinsky +4 · 1 citation
Pharmacology, Toxicology and Pharmaceutics · Medicine · Biochemistry, Genetics and Molecular Biology · #Forensic Toxicology and Drug Analysis #Diet and metabolism studies #Muscle metabolism and nutrition
paper · doi:10.1097/fbp.0b013e32833b3397
openalex publication_date 2010/06/03 · openalex created_date 2016/06/24 · openalex updated_date 2026/07/30
Despite the therapeutic use and abuse potential of gamma-hydroxybutyrate (GHB or Xyrem), relatively few studies have examined the behavioral effects of GHB in humans under controlled laboratory conditions. Thus, this eight-session study examined in 10 non-substance-abusing volunteers the behavioral effects of GHB at each of the following doses: 0, 0.32, 0.56, 0.75, 1.0, 1.8, 2.4, 3.2 g/70 kg, orally. Order of dose testing was random, except that the first two participants received active doses in ascending order and 2.4 g/70 kg was always tested before 3.2 g/70 kg. Before drug administration and at several postdrug time points, self-report, observer report, physiological, and psychomotor performance measures were obtained. Analyses based on area under the curve showed that GHB produced dose-related increases in subjective ratings of sedative-like, stimulant-like, positive mood, and dissociative effects, but no changes in psychomotor performance measures or blood pressure. Analyses based on peak effects generally showed dose-related increases in ratings indicating sedative-like, dissociative, and drug liking, although some measures showed U-shaped dose-related changes. These initial findings suggest that GHB at doses of 0.32-3.2 g/70 kg produces dissociative, sedating and some stimulant-like effects in humans without a history of sedative abuse.